4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-23-005908
Chief Financial Officer sold 924 shares at $11.78 ($10,884)
- Chief Financial Officer acquired 2,886 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| van Houte Hans Chief Financial Officer | 2023-01-30 | Option exercise | +2,886 | 77,689 | D: show line 1 in the form | ||
| van Houte Hans Chief Financial Officer | 2023-01-30 | Sale | −924 | $11.78 | $10,884 | 76,765 | D: show line 2 in the form |
| Open-market sales · 924 sh · avg $11.78 · $10,884 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| van Houte Hans Chief Financial Officer | 2023-01-30 | Option exercise · Restricted Stock Units | −2,886 | 34,633 | D: show line 3 in the form |
Loading xslF345X03/doc4.xml…